Dr. Dino PratoEnvita Medical Centers · Founder and CEO at Envita Medical Centers

Is CPI better than mRNA cancer vaccines? #shorts

19 Mar 2026 · 0 min

Watch on YouTube

0:29

In this YouTube short, Dr. Dino Prato contrasts the limited neoantigen repertoire of Moderna’s mRNA cancer vaccine—approximately 34 neoantigens—with the broader potential of custom-developed immunotherapies. He argues that a personalized approach is essential because the vaccine’s narrow target set restricts its effectiveness. Prato then introduces his “invisible surgery” technique: a hair‑sized catheter that delivers a bespoke chemo‑immuno cocktail and transcriptomics‑derived biomarker targets directly into the tumor. This direct‑to‑tumor injection aims to shut down tumor growth pathways, robustly stimulate T‑cell responses, and diminish the tumor’s ability to evade immune attack.

In the Moderna vaccine, you have, let's say, 34 neoantigens, but that's all you have. That's why building custom immunotherapy is so important. Direct-to-tumor chemo-immuno precision injection using non-invasive, or what I like to call invisible surgery, a catheter the size of a hair, delivering custom-developed immunotherapy and transcriptomics biomarker targets directly to the tumor so we can shut down its growth pathway, get the T cells to get stimulated, and now give a less of a chance of the tumor evading.